Does insurance cover Mounjaro in Illinois?

If you’re considering medications like Wegovy, Ozempic, or Mounjaro for weight loss or diabetes management, one of your first questions is probably: Will my insurance cover it? The answer isn’t always straightforward. Coverage varies widely depending on your insurance type, the specific medication, and how it’s prescribed. In 2025, the landscape of GLP-1 drug coverage is evolving rapidly—with some promising changes for accessibility, but also new restrictions that may affect your options.

This guide breaks down everything you need to know about insurance coverage for these breakthrough medications, including what to expect from commercial plans, Medicare, and Medicaid, as well as how to navigate denials and find affordable alternatives.

Understanding GLP-1 Medications: What’s the Difference?

Before diving into insurance coverage, it’s important to understand what these medications are and how they differ:

Wegovy (semaglutide) is FDA-approved specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related health condition. It’s the same active ingredient as Ozempic, but at higher doses tailored for weight loss.

Ozempic (semaglutide) is FDA-approved for Type 2 diabetes management. While many people use it off-label for weight loss due to its appetite-suppressing effects, insurers typically only cover Ozempic when prescribed for diabetes treatment.

Mounjaro (tirzepatide) is approved for Type 2 diabetes and works through a dual mechanism (GLP-1 and GIP receptors). Like Ozempic, it’s often sought for weight loss, but insurance coverage is generally limited to diabetes indications. A separate formulation called Zepbound is FDA-approved for obesity, though coverage remains limited.

The key distinction for insurance purposes is what condition the medication is treating. Diabetes medications generally have broader coverage, while weight-loss drugs face more barriers.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Commercial Insurance Coverage: What to Expect

Coverage for Diabetes vs. Weight Loss

If you have private health insurance through your employer or the Marketplace, here’s what coverage typically looks like:

For diabetes treatment (Ozempic, Mounjaro): Most commercial plans cover these medications when prescribed for Type 2 diabetes, as diabetes management is considered an essential health benefit. However, you’ll likely need:

• A confirmed Type 2 diabetes diagnosis
• Documentation that you’ve tried first-line treatments like metformin
• Prior authorization from your doctor
• Placement in a higher formulary tier (Tier 3 or Tier 4), meaning higher copays or coinsurance

For weight loss (Wegovy): Coverage is far less certain. Many employer plans exclude anti-obesity medications altogether as ‘optional’ benefits due to their high cost—around $1,350 per month at list price. Plans that do cover Wegovy typically require:

• BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (such as hypertension, Type 2 diabetes, or sleep apnea)
• Documentation of at least 6 months of supervised diet and exercise programs
• Prior authorization with detailed medical records
• Sometimes, evidence that you’ve tried other weight-loss medications first

Even when covered, insurers often place weight-loss medications in specialty tiers with 25-40% coinsurance rather than flat copays, making monthly out-of-pocket costs significant.

Prior Authorization: The Main Hurdle

Nearly all GLP-1 medications require prior authorization (PA), regardless of the indication. This means your doctor must submit documentation proving medical necessity before insurance will approve coverage. The PA process typically includes:

• Detailed medical history and diagnosis codes
• Current BMI and weight-related health conditions
• Records of previous weight-loss attempts or diabetes treatments
• Treatment plan and expected outcomes

Approval timelines vary but generally take 5-7 business days for initial requests. If approved, coverage is often authorized for 3-6 months initially, with re-evaluation required to demonstrate you’re meeting weight-loss targets (typically ≥5% weight loss) or diabetes control goals.

Why Denials Happen

Insurance denials for GLP-1 medications are common. The most frequent reasons include:

1. Plan exclusion: Your policy simply doesn’t cover weight-loss drugs, period
2. Insufficient documentation: Missing records of diet/exercise attempts or BMI measurements
3. Not meeting criteria: BMI below threshold or lacking required comorbidities
4. Off-label use: Requesting Ozempic for weight loss when you don’t have diabetes
5. Step therapy failure: Not trying required cheaper alternatives first

Understanding why your claim was denied is crucial for a successful appeal.

Medicare Coverage: Limited but Expanding

Traditional Medicare Part D does not cover medications prescribed solely for weight loss—this is written into federal law. The statute excludes ‘drugs used for weight loss’ from Part D coverage, which means Wegovy, Zepbound, and similar obesity medications are generally not covered.

However, there’s an important exception: Medicare will cover these medications for other FDA-approved uses. In March 2024, Medicare began covering Wegovy for cardiovascular risk reduction in patients with established heart disease and obesity. If you have both obesity and cardiovascular disease, your doctor may be able to prescribe Wegovy under this indication, and Medicare Part D would cover it.

For diabetes medications like Ozempic and Mounjaro, Medicare Part D covers them just like other diabetes drugs, typically placing them in higher cost-sharing tiers. You’ll still need prior authorization confirming your diabetes diagnosis and treatment history.

Medicare Advantage plans have slightly more flexibility. Some MA plans in 2025 have started offering limited coverage for weight-loss medications as supplemental benefits, though this varies widely by plan and region. Always check your specific plan’s formulary.

Medicaid Coverage: A State-by-State Patchwork

Medicaid coverage for GLP-1 weight-loss medications is extremely variable because states have the option to cover or exclude these drugs. As of late 2025, only about 13 states provide Medicaid coverage for obesity medications, and even this is shrinking due to budget pressures.

State-Specific Coverage Highlights

California: Medi-Cal covered Wegovy with prior authorization through 2025, but coverage ends January 1, 2026 for adults due to state budget cuts. Pediatric patients may still receive coverage under EPSDT (Early and Periodic Screening, Diagnostic, and Treatment) provisions.

Pennsylvania: Medicaid covered Wegovy for eligible adults with strict PA criteria (BMI ≥30 or ≥27 with comorbidities, documented lifestyle interventions). However, coverage is being discontinued in January 2026 following budget constraints.

New York: NYRx continues to cover Wegovy with prior authorization, requiring BMI thresholds, documented weight-related conditions, and lifestyle modification attempts.

Texas, Florida, and Illinois: These states do not cover weight-loss medications through Medicaid for adults. Texas explicitly excludes all obesity medications for members age 21 and older, though exceptions may be made for children under EPSDT.

For states that do cover obesity medications, the criteria are typically more stringent than commercial insurance:

• BMI ≥35 (or ≥30 with significant comorbidities)
• Extensive documentation of 6-12 months of diet and exercise
• Regular follow-up appointments to monitor progress
• Quantity limits (often 4 pens per 28 days)

If you have dual eligibility (both Medicare and Medicaid), Medicaid may cover Wegovy since Medicare doesn’t—but check your state’s specific rules.

What If Insurance Denies Coverage? Your Options

1. Appeal the Denial

If your initial request is denied, don’t give up. Appeals can be successful, especially if the denial was based on missing documentation or misinterpretation of criteria. To strengthen your appeal:

• Ask your doctor to submit a letter of medical necessity detailing your health risks and why this medication is appropriate
• Provide complete documentation of your weight-loss attempts, comorbidities, and current health status
• Include peer-reviewed studies showing the medication’s effectiveness for your condition
• Reference your plan’s own coverage criteria and demonstrate how you meet each requirement

Appeal timelines vary, but expect 2-3 weeks for resolution. Some plans offer expedited appeals for urgent medical needs.

2. Manufacturer Savings Programs

Both Novo Nordisk and Eli Lilly offer substantial savings options:

Novo Nordisk programs:

• Savings Card for commercially insured patients: Can reduce Wegovy or Ozempic copays to as low as $0-$25 per month (typically up to $225 off monthly)
• Self-pay option through NovoCare: Wegovy at $349/month (down from nearly $1,400 list price)
• Patient Assistance Program: Free medication for qualifying low-income, uninsured patients

Eli Lilly programs:

• Mounjaro Savings Card: $25 per month for commercially insured patients with Type 2 diabetes
• Zepbound self-pay: Single-dose vials now $299-$449 depending on strength (through LillyDirect)
• Patient Assistance Program: Free or reduced-cost medication based on income

Important note: Manufacturer copay cards cannot be used with government insurance (Medicare, Medicaid) but work with most commercial plans.

3. GoodRx and Discount Programs

In November 2025, GoodRx partnered with Novo Nordisk to offer unprecedented cash pricing:

• $199/month for the first two prescriptions of Wegovy or Ozempic
• $349/month ongoing pricing for most doses
• Available at nearly all pharmacies nationwide

This represents a 60-70% discount from list prices and makes self-pay much more accessible for those without coverage. Simply present the GoodRx coupon at your pharmacy—no insurance needed.

4. Consider Alternative Medications

If newer GLP-1s remain unaffordable, discuss these options with your doctor:

For weight loss:

• Older GLP-1s like Saxenda (liraglutide) may have broader insurance coverage
• Phentermine or combination medications like Qsymia are significantly cheaper ($30-$100/month)
• Metformin (for prediabetes or PCOS) is inexpensive and may help with modest weight loss

For diabetes:

• SGLT2 inhibitors or DPP-4 inhibitors may be preferred by your plan
• Older diabetes medications like metformin or sulfonylureas cost much less

While these may not be as effective as newer GLP-1s, they can provide benefits while you work on securing coverage for your preferred medication.

5. Explore Telehealth Options with Transparent Pricing

Many traditional insurance plans make accessing GLP-1 medications complicated and expensive. Klarity Health offers an alternative approach with:

• Transparent, upfront pricing for both consultations and medications—no surprise bills
• Fast provider availability to reduce wait times for prescriptions and ongoing care
• Acceptance of both insurance and self-pay, giving you flexibility in how you pay
• Virtual visits that save time and make weight management support more accessible

Whether your insurance covers your medication or you’re paying cash, knowing exactly what you’ll pay and getting quick access to qualified providers can make your weight-loss journey less stressful and more sustainable.

The Telehealth Advantage: Coverage and Convenience

The good news for virtual care: most insurance plans now cover telehealth visits for weight management just as they would in-person appointments. Since the pandemic, over 40 states have enacted telehealth parity laws requiring private insurers to cover virtual care equivalently to office visits.

This means:

• Your nutritional counseling, doctor consultations, and follow-up visits can be done virtually and covered by insurance
• Many plans cover obesity prevention counseling as a no-cost preventive service
• Telehealth visits typically have the same copay as in-person visits if using an in-network provider

Check with your specific plan about:

• Network requirements for telehealth providers
• Whether live video is required (versus phone-only)
• Any visit limits or prior authorization needs

Platforms like Klarity Health make accessing weight-loss support convenient by offering virtual consultations with licensed providers who can prescribe medications, provide lifestyle coaching, and coordinate with your insurance—all from home.

Key Coverage Takeaways

For Commercial Insurance:

• Diabetes medications (Ozempic, Mounjaro) are generally covered with prior authorization
• Weight-loss medications (Wegovy) have limited, highly restrictive coverage
• Expect high cost-sharing even when covered (Tier 3-4 placement)
• Prior authorization is nearly universal and can take 1-2 weeks

For Medicare:

• Part D covers diabetes GLP-1s but excludes weight-loss drugs
• Exception: Wegovy covered for cardiovascular risk reduction
• Medicare Advantage may offer limited obesity drug coverage as supplemental benefit

For Medicaid:

• Extremely state-dependent; most states don’t cover weight-loss drugs
• Coverage is shrinking in 2026 as states cut budgets (California, Pennsylvania)
• Strict criteria and quantity limits in states that do cover
• Pediatric coverage may be available under EPSDT even when adult coverage is denied

Self-Pay Options in 2025:

• GoodRx: $199-$349/month for Wegovy/Ozempic
• Manufacturer programs: $0-$25 copays with insurance, $299-$449 self-pay options
• Patient assistance available for low-income, uninsured patients

Making Coverage Work for You

Navigating insurance coverage for GLP-1 medications requires persistence and preparation. Here’s your action plan:

1. Check your formulary: Look up your specific plan’s coverage of Wegovy, Ozempic, or Mounjaro on your insurer’s website
2. Understand the criteria: Note the BMI requirements, comorbidity needs, and step therapy rules
3. Document everything: Keep records of your weight-loss attempts, medical history, and current health conditions
4. Work with your provider: A detailed letter of medical necessity can make or break your approval
5. Be ready to appeal: Many initial denials are overturned with proper documentation
6. Know your alternatives: Have backup plans if insurance won’t cover your first choice

The insurance landscape for weight-loss medications is changing rapidly. While barriers remain high, new manufacturer pricing programs, expanding telehealth access, and growing recognition of obesity as a chronic disease are slowly improving access. Whether you’re working with insurance or considering self-pay options, understanding your choices empowers you to take control of your health journey.

If you’re ready to explore weight management support with transparent pricing and fast provider access, Klarity Health offers virtual consultations that accept both insurance and cash pay—giving you clarity and control over your care.

Research Currency Statement

Verified coverage status and pricing are accurate as of December 17, 2025. Always check your own insurance formulary for the latest details, as policies can change with new plan years.

Citations

1. Aetna Clinical Policy Bulletin – Weight Loss GLP-1 Agonists (May 2024). Available at: www.aetna.com

2. California DHCS Medi-Cal Announcement (December 2025). Available at: www.cmadocs.org

3. KFF Issue Brief – Medicaid Coverage of GLP-1s (November 2024). Available at: www.kff.org

4. GoodRx Press Release – New Weight Loss Pricing Program (November 17, 2025). Available at: www.businesswire.com

5. Pennsylvania Health Law Project – PA Medicaid Coverage of Newer Weight Loss Drugs (August 2024). Available at: www.phlp.org

Source:

• https://www.aetna.com/products/rxnonmedicare/data/2024/WeightLoss%28BMI%2035%29GIP-GLP-1GLP-1AgonistsPAwithLimit6450-CUDR_05-2024.html#:~:text=%C2%B0Wegovy%3A%20Initial%20therapy%20DOA%3A%207,based%20on%20the%20following%20references
• https://www.singlecare.com/blog/cigna-prior-authorization-weight-loss/#:~:text=Cigna%20coverage%20criteria%20for%20GLP,drugs
• https://www.amwinsconnect.com/news/kaiser-permanenter-coverage-changes-glp-1-drugs-and-anti-obesity-medications-2025#:~:text=drugs%20and%20other%20AOMs%20will,with%20BMI%20less%20than%2040
• https://www.texaschildrenshealthplan.org/2023/04/28/provider-alert-non-formulary-requests-for-obesity-control-drugs#:~:text=for%20obesity%20control%20drugs%20for,Imcivree%2C%20Qysmia%2C%20Saxenda%20and%20Wegovy
• https://www.phlp.org/en/news/pennsylvania-medicaid-covers-newer-weight-loss-drugs#:~:text=Generally%2C%20to%20get%20these%20drugs,CDC%29%20charts
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=What%20You%20Need%20to%20Know%3A,Cal%20managed%20care
• https://solutionshortcut.com/medicaid-drug-coverage-by-state-2025-2026-updates/#:~:text=VDP%20PDL%20%26%20criteria%3B%20last,com
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=%2A%20Three%20GLP,covered%20after%20January%201%2C%202026
• https://www.forbes.com/sites/joshuacohen/2025/08/07/coverage-of-weight-loss-drugs-by-medicaid-plans-continues-to-lag/#:~:text=Medicaid%2C%20a%20federal,employees%20due%20to%20cost%20concerns
• https://www.fiercepharma.com/marketing/novo-unveils-newly-reduced-self-pay-prices-wegovy-ozempic-after-white-house-deal#:~:text=Novo%20revealed%20Monday%20that%20the,will%20still%20run%20for%20%24499